For Research Use Only. Not for human consumption. The following summarizes published preclinical/clinical literature for laboratory research purposes only. Not a substitute for or alternative to any approved medication.
What It Is
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, cell-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, forming 1-methylnicotinamide (1-MNA). While technically a quinolinium-based small molecule rather than a peptide, it is frequently studied and sold alongside research peptides due to its role in the same metabolic-research space. NNMT sits at the intersection of the NAD+ salvage pathway and cellular methylation capacity, and elevated adipose NNMT expression has been consistently associated with obesity and insulin resistance in the published literature Li et al., Frontiers in Pharmacology, 2024.
Summary of Published Research Findings
The rationale for NNMT as a research target originated with Kraus et al., who reported that NNMT knockdown using antisense oligonucleotides protected mice against diet-induced obesity, increasing energy expenditure and improving insulin sensitivity Kraus et al., Nature, 2014. Building on this target-validation work, Neelakantan et al. developed and characterized selective, membrane-permeable small-molecule NNMT inhibitors — including 5-amino-1MQ — and reported that treatment reversed high-fat-diet-induced obesity measures in mice, reducing body weight and improving plasma lipid profiles relative to controls Neelakantan et al., Biochemical Pharmacology, 2017.
Subsequent studies from the same research group examined combination approaches. Dimet-Wiley et al. reported that combining NNMT inhibitor treatment with a reduced-calorie diet in diet-induced obese (DIO) mice normalized body composition more effectively than caloric restriction alone, decreasing liver and epididymal white adipose tissue weight while increasing lean-mass-to-body-weight ratio Dimet-Wiley et al., Scientific Reports, 2021. A related study from the same lab reported that combined NNMT inhibition and low-fat diet substitution produced a distinct gut microbiome signature in DIO mice compared to diet switching alone Eswar et al., Scientific Reports, 2022.
Epidemiological research has linked serum 1-methylnicotinamide (the direct product of NNMT activity) to obesity and diabetes risk in human cohort data, supporting the enzyme’s relevance as a metabolic biomarker and research target Zhu et al., Journal of Clinical Endocrinology & Metabolism, 2015.
Proposed Mechanism of Action
The mechanism proposed across this body of literature centers on restoring cellular NAD+ and S-adenosylmethionine (SAM) availability. NNMT normally consumes SAM (a universal methyl donor) and nicotinamide (an NAD+ precursor) to produce 1-MNA. Elevated NNMT activity in adipose and hepatic tissue is proposed to divert these substrates away from methylation reactions and NAD+ salvage, thereby favoring lipid storage and reducing energy expenditure Kraus et al., Nature, 2014. By selectively and reversibly inhibiting the NNMT enzyme, 5-amino-1MQ is proposed in preclinical models to preserve intracellular SAM and NAD+ pools, which researchers have linked to increased adipocyte energy expenditure, reduced lipogenesis, and improved insulin sensitivity in diet-induced obese mouse models Neelakantan et al., Biochemical Pharmacology, 2017.
Research Use Only / Handling Note
5-Amino-1MQ 5mg is supplied exclusively for laboratory research purposes, such as in vitro adipocyte assays (e.g., 3T3-L1 cell models) or diet-induced obesity studies in animal models conducted by qualified investigators. It is not intended for human or animal consumption, clinical use, or diagnostic application.